Phase II Pediatric Results A Boost For Replidyne’s Faropenem
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will not make a commitment to pursuing a Phase III trial for the antibiotic until a second-quarter meeting with FDA.